Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00329329
Other study ID # SAT1-05-02
Secondary ID
Status Terminated
Phase Phase 1
First received May 22, 2006
Last updated March 21, 2012
Start date May 2006
Est. completion date February 2009

Study information

Verified date March 2012
Source Agennix
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the maximally tolerated dose (MTD) and Phase 2 recommended dose of satraplatin when administered in combination with capecitabine in patients with advanced solid malignancies.


Description:

This is a single center, open-label, non-randomized, Phase I dose finding study of the investigational, oral cytotoxic drug, satraplatin in combination with capecitabine in patients with advanced solid tumors for whom curative therapy is not available. Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria.

PURPOSE: The purpose of this trial is to determine a tolerable dose and schedule for the combination of satraplatin and docetaxel when given to patients with advanced solid tumors.

WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.


Recruitment information / eligibility

Status Terminated
Enrollment 24
Est. completion date February 2009
Est. primary completion date January 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Key Inclusion Criteria:

- Histologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative chemotherapy measures do not exist or are no longer effective

- Age > 18 years old

- ECOG Performance Status < 2

- Female patients may not be pregnant or lactating and must be willing to practice contraception

- Adequate organ function as defined by the following:

- Serum creatinine < 1.5 mg/dl

- Absolute neutrophil count (ANC) > 1500/dL

- Platelets > 100,000/dL

- Total bilirubin < upper limit of normal (ULN) for the reference lab

- AST, ALT, and alkaline phosphatase must be within the designated range allowing for eligibility

Key Exclusion Criteria:

- Other chemotherapy treatment < 4 weeks prior to enrollment Treatment with capecitabine, 5-fluorouracil (5-FU), or a platinum agent < 3 months from time of enrollment

- Radiotherapy involving > 30% of the active bone marrow

- Radiotherapy < 4 weeks prior to enrollment

- Pre-existing peripheral neuropathy > grade 1

- Pre-existing hearing loss > grade 2

- Metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, had a negative imaging study within 4 weeks of study entry, is clinically stable with respect to the tumor at the time of study entry, and is not receiving steroid therapy or taper

- Patients who have not recovered (> grade 1) from the following toxicities of previous regimens before enrollment:

- hematologic toxicities

- fatigue

- mucositis

- nausea/vomiting

- diarrhea

- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)

- Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, uncontrolled congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements

- History of hypersensitivity reaction to capecitabine, 5-FU or any platinum containing drugs

- History of human immunodeficiency (HIV) or acquired immunodeficiency syndrome (AIDS) related illness

- Evidence of concurrent second malignancy other than basal cell carcinoma of the skin or cervical carcinoma in situ

- Concurrent use of medications that inhibit cytochrome P450 3A4 (including aprepitant)

- History of bone marrow or major organ transplant

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
satraplatin and capecitabine
satraplatin and capecitabine dose escalated per the dosing scheme

Locations

Country Name City State
United States Northwestern University Medical Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Agennix

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary MTD 2007 Yes
Secondary Safety 2007 Yes
See also
  Status Clinical Trial Phase
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT03236857 - A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Phase 1
Completed NCT03005782 - Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers Phase 1
Not yet recruiting NCT05602103 - Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
Completed NCT00316511 - Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma Phase 1
Withdrawn NCT05253105 - A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies Phase 1
Completed NCT02521389 - Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 Phase 1
Completed NCT01407380 - Study of PWT33597 Mesylate in Subjects With Advanced Malignancies Phase 1
Completed NCT01404728 - Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy N/A
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2
Not yet recruiting NCT05929495 - Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma Phase 2
Completed NCT02257476 - Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors Phase 1
Completed NCT00320827 - Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) Phase 1